Yıl: 2023 Cilt: 57 Sayı: 2 Sayfa Aralığı: 163 - 170 Metin Dili: İngilizce DOI: 10.14744/SEMB.2023.29560 İndeks Tarihi: 10-07-2023

Hypokinetic Dysarthria in Parkinson’s Disease: A Narrative Review

Öz:
Numerous disabling motor and non-motor symptoms occur during Parkinson’s disease (PD), including speech disorders, often referred to as hypokinetic dysarthria. PD is the most common cause of this type of dysarthria. About 90% of PD patients experi- ence hypokinetic dysarthria, which is exacerbated as the disease progresses and makes it very difficult for other people to under- stand the person with PD. This disorder is characterized by a monotonous speech pattern, reduced and monotonous loudness, decreased stress, a breathy or hoarse voice quality, an increase in speech rate, rapid repetition of phonemes, and impreciseness in consonant production. However, patients may also have sensory symptoms including inaccurate perceptions of their own loud- ness and decreased awareness of speech problems. Hypokinetic dysarthria in PD may not only result from dopamine degeneration in the nigrostriatal pathway but also from disturbances in the motor and somatosensory systems. All speech components, such as phonation, articulation, respiration, resonance, and prosody should be assessed carefully in PD patients with hypokinetic dysar- thria. Taking medical history, an oral motor assessment, a perceptual evaluation of speech characteristics, intelligibility, efficiency, and participation in communication all need to be a part of the assessment. The tasks of maximum phonation time, diadochoki- netic rate, reading sentences, words, and passages, describing pictures, and spontaneous speech are used to assess the features of speech components and intelligibility. The evaluation should include physiological, acoustic, or imaging modalities as well. Speech therapy is typically the main treatment of speech problems in PD. The management of PD-related hypokinetic dysarthria basically focuses on speaker-oriented and communication-oriented strategies. In addition to these strategies, Augmentative Alternative Communication (AAC) should be considered in patients with severe dysarthria. Loudness, intelligibility, and sound perception may all significantly improve with the Lee Silverman Voice Therapy LOUD (LSVT LOUD) program which is an evidence-based program. The beneficial effect of pharmacological and surgical treatment approaches has not been proven in improving speech. Deep brain stimulation may carry the risk of the deterioration of speech as the illness progresses.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık
  • 1. Freed DB. Motor Speech Disorders: Diagnosis and Treatment. 3rd ed. San Diego, CA: Plural Publishing; 2020.
  • 2. Schrag A, Horsfall L, Walters K, Noyce A, Petersen I. Prediagnostic presentations of Parkinson's disease in primary care: a case- control study. Lancet Neurol 2015;14:57−64. [CrossRef ]
  • 3. Moreau C, Pinto S. Misconceptions about speech impairment in Parkinson's disease. Mov Disord 2019;34:1471−5. [CrossRef ]
  • 4. McAuliffe MJ, Baylor CR, Yorkston KM. Variables associated with communicative participation in Parkinson's disease and its relationship to measures of health-related quality-of-life. Int J Speech Lang Pathol 2017; 19:407−7. [CrossRef ]
  • 5 Miller N, Noble E, Jones D, Burn D. Life with communication changes in Parkinson's disease. Age Ageing 2006;35:235−9. [CrossRef]
  • 6. Trail M, Fox C, Ramig LO, Sapir S, Howard J, Lai EC. Speech treatment for Parkinson's disease. Neuro Rehabilitation 2005;20:205−21. [CrossRef ]
  • 7. Miller N, Noble E, Jones D, Deane KH, Gibb C. Survey of speech and language therapy provision for people with Parkinson's disease in the United Kingdom: individuals' and carers' perspectives. Int J Lang Commun Disord 2011;46:179−88. [CrossRef ]
  • 8. Dashtipour K, Tafreshi A, Lee J, Crawley B. Speech disorders in Parkinson's disease: pathophysiology, medical management and surgical approaches. Neurodegener Dis Manag 2018;8:337−8. [CrossRef ]
  • 9. Hartelius L, Svensson P. Speech and swallowing symptoms associated with Parkinson's disease and multiple sclerosis: a survey. Folia Phoniatr Logop 1994;46:9−17. [CrossRef ]
  • 10. Duffy JR. Motor Speech Disorders: Substrates, Differential Diagnosis and Management. 3rd ed. St. Louis, MO: Mosby; 2013.
  • 11. American Speech-Language-Hearing Association (ASHA). Distinguishing Perceptual Characteristics and Physiologic Findings by Dysarthria Type. Available at: https://www.asha. org/practice-portal/clinical-topics/dysarthria-in-adults/ distinguishing-perceptual-characteristics/. Accessed Nov 20, 2022.
  • 12. Darling-White M, Huber JE. The impact of expiratory muscle strength training on speech breathing in individuals with Parkinson's disease: a preliminary study. Am J Speech Lang Pathol 2017;26:1159−66. [CrossRef ]
  • 13. Miller N. Communication changes in Parkinson's disease. Pract Neurol 2017;17:266−74. [CrossRef ]
  • 14. Lombard LE, Steinhauer KM. A novel treatment for hypophonic voice: twang therapy. J Voice 2007;21:294−9. [CrossRef ]
  • 15. Hegde MN, Freed D. Assessment of Communication Disorders in Adults: Resources and Protocols. 2nd ed. San Diego, CA: Plural Publishing; 2017.
  • 16. Ricciardi L, Ebreo M, Graziosi A, Barbuto M, Sorbera C, Morgante L, et al. Speech and gait in Parkinson's disease: when rhythm matters. Parkinsonism Relat Disord 2016;32:42−7. [CrossRef ]
  • 17. Walshe M, Miller N. Living with acquired dysarthria: the speaker's perspective. Disabil Rehabil 2011;33:195−203. [CrossRef ]
  • 18. Yorkston K, Baylor C, Britton D. Speech Versus Speaking: The Experiences of People with Parkinson's Disease and Implications for Intervention. Am J Speech Lang Pathol 2017;26:561−8. [CrossRef ]
  • 19. Pinto S, Ozsancak C, Tripoliti E, Thobois S, Limousin-Dowsey P, Auzou P. Treatments for dysarthria in Parkinson's disease. Lancet Neurol 2004;3:547−56. [CrossRef ]
  • 20. Ramig LO, Fox C, Sapir S. Speech treatment for Parkinson's disease. Expert Rev Neurother 2008;8:297−309. [CrossRef ]
  • 21. Liu H, Wang EQ, Metman LV, Larson CR. Vocal responses to perturbations in voice auditory feedback in individuals with Parkinson's disease. PloS One 2012;7:e33629. [CrossRef ]
  • 22. Ho AK, Bradshaw JL, Iansek T. Volume perception in parkinsonian speech. Mov Disord 2000;15:1125−31. [CrossRef ]
  • 23. Huang X, Chen X, Yan N, Jones JA, Wang EQ, Chen L, et al. The impact of Parkinson's disease on the cortical mechanisms that support auditory-motor integration for voice control. Hum Brain Mapp 2016;37:4248−61. [CrossRef ]
  • 24. Shipley KG, McAfee JG. Assessment in Speech-Language Pathology: A Resource Manual. 6th ed. San Diego, CA: Plural Publishing; 2021.
  • 25. Pindzola RH, Plexico LW, Haynes WO. Diagnosis and Evaluation in Speech Pathology. 9th ed. New York: Pearson; 2015.
  • 26. Oğuz Ö. Motor Konuşma Bozuklukları. Tanrıdağ O. Nörobilim ve Dil-Konuşma Bozuklukları. İstanbul: Nobel Tıp Kitabevleri; 2020.
  • 27. Patel RR, Awan SN, Barkmeier-Kraemer J, Courey M, Deliyski D, Eadie T, et al. Recommended protocols for instrumental assessment of voice: American Speech-Language-Hearing Association expert panel to develop a protocol for instrumental assessment of vocal function. Am J Speech Lang Pathol 2018;27:887−905. [CrossRef ]
  • 28. Rusz J, Tykalova T, Ramig LO, Tripoliti E. Guidelines for speech recording and acoustic analyses in dysarthrias of movement disorders. Mov Disord 2021;36:803−14. [CrossRef ]
  • 29. Altaher AM, Chu SY, Kam RBM, Razak RA. A report of assessment tools for individuals with dysarthria. Open Public Health J 2019;12:384−6. [CrossRef ]
  • 30. Boersma P, Weenink D. Praat: doing phonetics by computer. Version 6.1.08, 2019. Available at: http://www.praat.org/. Accessed Nov 20, 2022.
  • 31. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez- Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008;23:2129−70. [CrossRef ]
  • 32. Robertson SJ. Robertson Dysarthria Profile. Buckinghamshire: Winslow; 1982.
  • 33. Yorkston KM, Beukelman DR. Assessment of Intelligibility of Dysarthric Speech. Tigard, OR: C.C. Publications; 1981.
  • 34. Yorkston KM, Beukelman DR, Strand EA, Bell KR. Management of Motor Speech Disorders in Children and Adults. 2nd ed. Austin, TX: Pro Ed; 1999.
  • 35. Jacobson BH, Johnson A, Grywalski C, Silbergleit A, Jacobson G, Benninger MS, et al. The voice handicap index (VHI) development and validation. Am J Speech Lang Pathol 1997;6:66−70. [CrossRef ]
  • 36. Walshe M, Peach RK, Miller N. Dysarthria impact profile: development of a scale to measure psychosocial effects. Int J Lang Commun Disord 2009;44:693−715. [CrossRef ]
  • 37. Baylor C, Yorkston K, Eadie T, Kim J, Chung H, Amtmann D. The Communicative Participation Item Bank (CPIB): item bank calibration and development of a disorder-generic short form. J Speech Lang Hear Res 2013;56:1190−208. [CrossRef ]
  • 38. Donovan NJ. Examining the item-level psychometric properties of the communicative effectiveness survey-revised for people with Parkinson's disease and dysarthria. Clin Arch Commun Disord 2018;3:42−51. [CrossRef ]
  • 39. Schalling E, Johansson K, Hartelius L. Speech and communication changes reported by people with Parkinson's disease. Folia Phoniatr Logop 2017;69:131−41. [CrossRef ]
  • 40. Sackley CM, Smith CH, Rick C, Brady MC, Ives N, Patel R, et al. Lee Silverman voice treatment versus standard NHS speech and language therapy versus control in Parkinson's disease (PD COMM pilot): study protocol for a randomized controlled trial. Trials 2014;15:213. [CrossRef ]
  • 41. Ramig L, Halpern A, Spielman J, Fox C, Freeman K. Speech treatment in Parkinson's disease: randomized controlled trial (RCT). Mov Disord 2018;33:1777−91. [CrossRef ]
  • 42. Fox C, Ebersbach G, Ramig L, Sapir S. LSVT LOUD and LSVT BIG: behavioral treatment programs for speech and body movement in Parkinson disease. Parkinsons Dis 2012:391946. [CrossRef ]
  • 43. Atkinson-Clement C, Sadat J, Pinto S. Behavioral treatments for speech in Parkinson's disease: meta-analyses and review of the literature. Neurodegener Dis Manag 2015;5:233−48. [CrossRef ]
  • 44. Levitt JS, Walker-Batson D. The effects of the "Speak with Intent" instruction for individuals with Parkinson's disease. J Commun Disorder Assist Technol 2018;1:1−15.
  • 45. Tjaden K. Speech and swallowing in Parkinson's disease. Top Geriatr Rehabil 2008;24:115−26. [CrossRef ]
  • 46. Fernandez HH, Walter BL, Rush TE, Ahmed A. A Practical Approach to Movement Disorders: Diagnosis and Management. 3rd ed. New York: Springer Publishing Company; 2021. [CrossRef ]
  • 47. Tykalová T, Rusz J, Čmejla R, Klempíř J, Růžičková H, Roth J, et al. Effect of dopaminergic medication on speech dysfluency in Parkinson's disease: a longitudinal study. J Neural Transm 2015;122:1135−42. [CrossRef ]
  • 48. Schulz GM, Peterson T, Sapienza CM, Greer M, Friedman W. Voice and speech characteristics of persons with Parkinson's disease pre- and post-pallidotomy surgery: preliminary findings. J Speech Lang Hear Res 1999;42:1176−94. [CrossRef ]
  • 49. Tröster AI, Woods SP, Fields JA, Hanisch C, Beatty WW. Declines in switching underlie verbal fluency changes after unilateral pallidal surgery in Parkinson's disease. Brain Cogn 2002;50:207−17. [CrossRef ]
  • 50. Moreau C, Pennel-Ployart O, Pinto S, Plachez A, Annic A, Viallet F, et al. Modulation of dysarthropneumophonia by low- frequency STN DBS in advanced Parkinson's disease. Mov Disord 2011;26:659−63. [CrossRef ]
APA sapmaz m, OGUZ O, Genc G (2023). Hypokinetic Dysarthria in Parkinson’s Disease: A Narrative Review. , 163 - 170. 10.14744/SEMB.2023.29560
Chicago sapmaz merve,OGUZ OZLEM,Genc Gencer Hypokinetic Dysarthria in Parkinson’s Disease: A Narrative Review. (2023): 163 - 170. 10.14744/SEMB.2023.29560
MLA sapmaz merve,OGUZ OZLEM,Genc Gencer Hypokinetic Dysarthria in Parkinson’s Disease: A Narrative Review. , 2023, ss.163 - 170. 10.14744/SEMB.2023.29560
AMA sapmaz m,OGUZ O,Genc G Hypokinetic Dysarthria in Parkinson’s Disease: A Narrative Review. . 2023; 163 - 170. 10.14744/SEMB.2023.29560
Vancouver sapmaz m,OGUZ O,Genc G Hypokinetic Dysarthria in Parkinson’s Disease: A Narrative Review. . 2023; 163 - 170. 10.14744/SEMB.2023.29560
IEEE sapmaz m,OGUZ O,Genc G "Hypokinetic Dysarthria in Parkinson’s Disease: A Narrative Review." , ss.163 - 170, 2023. 10.14744/SEMB.2023.29560
ISNAD sapmaz, merve vd. "Hypokinetic Dysarthria in Parkinson’s Disease: A Narrative Review". (2023), 163-170. https://doi.org/10.14744/SEMB.2023.29560
APA sapmaz m, OGUZ O, Genc G (2023). Hypokinetic Dysarthria in Parkinson’s Disease: A Narrative Review. Şişli Etfal Hastanesi Tıp Bülteni, 57(2), 163 - 170. 10.14744/SEMB.2023.29560
Chicago sapmaz merve,OGUZ OZLEM,Genc Gencer Hypokinetic Dysarthria in Parkinson’s Disease: A Narrative Review. Şişli Etfal Hastanesi Tıp Bülteni 57, no.2 (2023): 163 - 170. 10.14744/SEMB.2023.29560
MLA sapmaz merve,OGUZ OZLEM,Genc Gencer Hypokinetic Dysarthria in Parkinson’s Disease: A Narrative Review. Şişli Etfal Hastanesi Tıp Bülteni, vol.57, no.2, 2023, ss.163 - 170. 10.14744/SEMB.2023.29560
AMA sapmaz m,OGUZ O,Genc G Hypokinetic Dysarthria in Parkinson’s Disease: A Narrative Review. Şişli Etfal Hastanesi Tıp Bülteni. 2023; 57(2): 163 - 170. 10.14744/SEMB.2023.29560
Vancouver sapmaz m,OGUZ O,Genc G Hypokinetic Dysarthria in Parkinson’s Disease: A Narrative Review. Şişli Etfal Hastanesi Tıp Bülteni. 2023; 57(2): 163 - 170. 10.14744/SEMB.2023.29560
IEEE sapmaz m,OGUZ O,Genc G "Hypokinetic Dysarthria in Parkinson’s Disease: A Narrative Review." Şişli Etfal Hastanesi Tıp Bülteni, 57, ss.163 - 170, 2023. 10.14744/SEMB.2023.29560
ISNAD sapmaz, merve vd. "Hypokinetic Dysarthria in Parkinson’s Disease: A Narrative Review". Şişli Etfal Hastanesi Tıp Bülteni 57/2 (2023), 163-170. https://doi.org/10.14744/SEMB.2023.29560